[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
May 27, 2009

Efalizumab Withdrawn

JAMA. 2009;301(20):2085. doi:10.1001/jama.2009.712

After several actions by the US Food and Drug Administration (FDA) to alert physicians about reports of a rare and deadly neurological disorder developing in patients treated with efalizumab for psoriasis, the drug's maker is voluntarily removing the drug from the market, according to an announcement by the FDA (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01992.html).

First Page Preview View Large
First page PDF preview
First page PDF preview
×